The relationship between the COPD Assessment Test score and airflow limitation in Japan in patients aged over 40 years with a smoking history. by Yoshimoto, D et al.
© 2014 Yoshimoto et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of COPD 2014:9 1357–1363
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1357
P e r s P e C t I v e s
open access to scientific and medical research
Open Access Full text Article
http://dx.doi.org/10.2147/COPD.S61265
the relationship between the COPD Assessment 
Test score and airflow limitation in Japan in 
patients aged over 40 years with a smoking history
Daisuke Yoshimoto1
Yasutaka Nakano2
Katsuya Onishi3
Gerry Hagan4
Paul Jones5
1GlaxosmithKline, tokyo, 2Division of 
respiratory Medicine, Department of 
Medicine, shiga University of Medical 
science, Otsu, 3Onishi Heart Clinic, 
tsu, Japan; 4Independent consultant, 
Marbella, spain; 5Division of Clinical 
science, st George’s Hospital, 
University of London, London, UK
Correspondence: Paul Jones 
Division of Clinical science, st George’s 
Hospital, University of London,  
London, UK 
tel +44 20 8672 9944 
email pjones@sgul.ac.uk
Background: A large number of chronic obstructive pulmonary disease (COPD) patients 
in Japan remain undiagnosed, primarily due to the underuse of spirometry. Two studies were 
conducted to see whether the COPD Assessment Test (CAT) in primary care has the potential to 
identify those patients who need spirometry for a diagnosis of COPD and to determine whether 
patients with cardiovascular disease had airflow limitation, which could be detected by CAT.
Materials and methods: Two multicenter, noninterventional, prospective studies (studies 1 
and 2) were conducted across Japan. Patients in both studies were $40 years old with a smoking 
history. Those in study 1 were seen in primary care and had experienced repeated respiratory tract 
infections, but had no diagnosis of COPD. Patients in study 2 were identified in cardiovascular 
disease clinics when routinely visiting for their cardiovascular disease. All patients completed the 
CAT prior to lung-function testing by hand-held spirometry. The presence of airflow limitation 
was defined as a forced expiratory volume in 1 second (FEV
1
)/FEV
6
 ratio ,0.73.
Results: A total of 3,062 subjects completed the CAT (2,067 in study 1, 995 in study 2); 88.8% 
were male, and the mean age (± standard deviation) was 61.5±11.6 years. Airflow limitation was 
found in 400 (19.4%) patients in study 1, and 269 (27.0%) in study 2. The CAT score in patients 
with airflow limitation was significantly higher than in patients without airflow limitation in both 
studies: 8.6 (95% confidence interval [CI] 7.9–9.2) versus 7.4 (95% CI 7.1–7.6) in study 1, and 
8.3 (95% CI 7.5–9.2) versus 6.4 (95% CI 6.0–6.8) in study 2 (both P,0.001).
Conclusion: These findings suggest that the CAT has the potential to identify patients with 
cardiovascular disease or a history of frequent chest infections who need spirometry to diag-
nose COPD.
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Introduction
The prevalence of chronic obstructive disease (COPD) is expected to increase through-
out the world.1–3 There are few data available on the prevalence of airflow limita-
tion in Japan. The prevalence of airflow limitation has been reported to range from 
10.9% in the NICE study4 to 13.9% in another study.5 There is, however, a significant 
underdiagnosis of COPD in Japan, because of insufficient use of spirometry6 and 
also underrecognition by physicians, so these figures are likely to be underestimates.4 
The high prevalence of smoking coupled with an aging population threatens to further 
increase the burden of COPD, highlighting the need for enhanced screening efforts and 
interventions for prevention and treatment.4 Previous data have shown that screening 
spirometry during medical checkups can identify many COPD patients not aware of 
this disease.7 The study using a hand-held spirometer showed that underdiagnosis of 
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COPD was  particularly a problem in patients with chronic 
bronchitis and in younger patients,8 a phenotype that is not 
usually recognized as COPD in Japan.
The diagnosis of COPD requires measurement of forced 
expiratory volume in 1 second (FEV
1
)1. However, as COPD 
can affect health status independently of the level of airflow 
limitation,9 questionnaires have been developed to assess the 
impact of COPD on health status. The COPD Assessment Test 
(CAT) was developed as a simple tool for assessing the impact 
of COPD on health status that can easily be used in primary 
care.10,11 It is an eight-item questionnaire documenting the 
subject’s evaluation of symptoms and their impact.
The aim of this paper was to test whether the CAT 
could be a useful tool to find subjects who should have 
spirometry to assess whether they have COPD. This could 
potentially improve the uptake of spirometry in the clinic 
by promising a higher success rate of diagnosis than ran-
dom use of spirometry in smokers. It could also lead to 
a simple way for patients to check their own score and 
request spirometry from their physician if their score war-
ranted it. The CAT scores from two previous studies have 
therefore been  evaluated. The aim of the first study was to 
determine whether patients being treated for winter bron-
chitis in primary care included a proportion of patients who 
had undiagnosed COPD, and the second was designed to 
determine whether a proportion of patients being seen in 
cardiovascular disease clinics had airflow limitation that 
could be detected by the CAT.
Materials and methods
In study 1, patients were recruited consecutively between 
February 2012 and April 2012 at 15 centers in Japan. In 
study 2, patients were recruited consecutively between 2012 
and 2013 at 17 centers in Japan. All patients gave written 
informed consent prior to any study-related procedures, and 
the protocol was approved by the appropriate institutional 
review boards.
Study 1 (GlaxoSmithKline [GSK] study code RES116549) 
was a screening survey to assess the rates of undiagnosed 
COPD in patients aged $40 years. Entry criteria included 
the need for recurrent antitussives and/or antibiotics for two 
or more chest infections in the last 2 years in current or ex-
smokers with a $10-pack-year smoking history. Patients 
with any diagnosed respiratory disease were excluded, as 
were patients with an acute respiratory event within 4 weeks 
prior to screening. Patients were not allowed to have taken 
any bronchodilator within 24 hours of the spirometry test. 
The data from this study regarding the symptoms of patients 
with undiagnosed airflow limitation have already been 
published.8
Study 2 (GSK study code RES116883) was a multi-
center prospective study in patients who routinely visited 
a clinic for their cardiovascular disease. Patients who were 
aged $40 years and had a smoking history completed the 
CAT and spirometry.
In both studies, assessments were performed at a single 
visit. Patients completed a CAT questionnaire. Each item was 
scored on a 6-point scale ranging from 0 to 5. The total score 
can thus range from 0 to 40, with higher scores representing 
greater impairment. Lung function was measured following 
the CAT using a hand-held spirometer (Hi-Checker; Takara 
Tsusho, Tokyo, Japan). The Hi-Checker has been previously 
demonstrated to be an accurate alternative to the conven-
tional spirometer.8 FEV
1
 and FEV
6
 were measured prior to 
bronchodilator use. Subjects performed forced expiration for 
6 seconds until reproducible FEV
6
 values were obtained (the 
difference between the two highest FEV
6
 values was not more 
than 0.10 L). Predicted FEV
1
 values were calculated accord-
ing to the formula used by the Lung Physiology Committee, 
Japanese Respiratory Society.12
Airflow limitation was def ined as an FEV
1
/FEV
6
 
ratio ,0.7313. The FEV
1
/FEV
6
 ratio can be used as a valid 
alternative for FEV
1
/FVC in the diagnosis of airway obstruc-
tion, especially for screening purposes in high-risk popula-
tions for COPD in primary care.13
statistical analysis
All data were processed and summarized by the use of SAS 
version 9.2 or higher. The percentage of patients who had a 
CAT score and airflow limitation versus those with a CAT 
score and no airflow limitation was analyzed by χ2 test. Other 
variables were analyzed by analysis of variance. A regression 
analysis between the CAT score and FEV
1
/FEV
6
 ratio was 
performed. False-negative and false-positive values were 
also calculated to give the sensitivity and specificity of CAT 
scores 7–10.
Results
A total of 3,062 patients – 2,067 in study 1 and 995 in 
study 2 – had a CAT score available. The mean age 
(± standard deviation) of patients was 61.5 (±11) years, and 
patients were predominantly male (88.8%). The character-
istics are shown in Table 1.
Airflow limitation was found in 400 patients (19.4%) 
and 269 patients (27%) in studies 1 and 2, respectively 
(Table 1). Of these, only 1.6% had a previous diagnosis of 
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Table 1 Patient baseline characteristics (total patients screened 
and by study)
Total 
(n=3,062)
Study 1 
(n=2,067)
Study 2 
(n=995)
Age, years
 Mean (sD) 61.5 (11.6) 59.0 (11.6) 66.6 (10.0)
sex
 Male 88.8% 85.5% 95.5%
smoking history
 Current 44.9% 53.4% 27.4%
 ex 55.1% 46.6% 72.6%
smoking, pack-years
 Mean (sD) 37.3 (23.5) 34.6 (21.6) 43.1 (26.1)
BMI
 Mean (sD) 24.1 (3.4) 23.9 (3.3) 24.6 (3.5)
Diagnosed with COPD
 Yes 1.6% 0 4.8%
Chronic sputum*
 Yes 19.7% 19.4% 20.4%
Fev1
 Mean (sD) 2.52 (0.76) 2.63 (0.76) 2.29 (0.70)
Fev6
 Mean (sD) 3.21 (0.86) 3.33 (0.88) 2.97 (0.79)
Airflow limitation
 Fev1/Fev6 ,0.73 21.8% 19.4% 27.0%
 Fev1/Fev6 $0.73 78.2% 80.6% 73.0%
CAt score
 Mean (sD) 7.4 (5.9) 7.6 (5.9) 6.9 (5.8)
Note: *Chronic sputum was diagnosed as sputum symptoms observed for at least 
3 months of the year for more than 2 consecutive years.
Abbreviations: sD, standard deviation; BMI, body mass index; COPD, chronic 
obstructive pulmonary disease; Fev1, forced expiratory volume in 1 second; 
Fev6, forced expiatory volume in 6 seconds; CAt, COPD Assessment test.
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Figure 1 CAT score in patients with airflow limitation (AL) and without AL.
Abbreviations: COPD, chronic obstructive pulmonary disease; CAt, COPD 
Assessment Test; CI confidence interval.
COPD (0% in study 1 and 4.8% in study 2). The CAT score in 
patients with airflow limitation was significantly higher than 
in patients without airflow limitation in both studies: 8.6 (95% 
confidence interval [CI] 7.9–9.2) versus 7.4 (95% CI 7.1–7.6) 
in study 1 (P,0.001) and 8.3 (95% CI 7.5–9.2) versus 6.4 
(95% CI 6.0–6.8) in study 2 (P,0.001) (Figure 1).
The demographics of patients in each CAT category are 
shown in Table 2. CAT score by age is shown in Figure 2. 
The degree of airflow limitation was significantly higher in 
patients with a higher CAT score (Table 2), eg, 19.6% of 
patients who had a CAT score between 0 and 9 had an FEV
1
/
FEV
6
 ratio ,0.73 compared with 33.8% of patients who had 
a CAT score between 20 and 29 (P,0.001). The number of 
patients with a previous diagnosis of COPD and the number 
of patients with chronic sputum significantly increased with 
worsening CAT score (Table 2). This was not however seen 
in patients in the highest CAT category (CAT 30+), as there 
were only six patients with airflow limitation in this group.
A summary of lung-function data for patients with and 
without airflow obstruction is shown in Table 3. The mean 
FEV
1
 in patients with airflow limitation and repeated chest 
infections in study 1 was 2.0 L, and in the correspond-
ing patients with cardiovascular disease in study 2 it was 
1.7 L. In patients without airflow limitation, these values 
were 2.8 L and 2.5 L, respectively.
The percentage of patients with airflow limitation 
 categorized by CAT score is shown in Figure 3. The  majority 
of patients with airflow limitation had a CAT score .7. 
The sensitivity and specificity of the CAT at different 
CAT cut points is shown in Table 4. It can be seen that the 
false-positive rate remained constant across the cut points 
selected, but the false-negative rate fell to 31% with a CAT 
of 10 compared to 66% with a CAT of 7.
Discussion
Data from these studies show that in patients aged >40 years 
with a smoking history and repeated chest infections or 
history of cardiovascular disease, the CAT has the potential 
to identify which patients should undergo spirometry. This 
confirms findings from another study performed using the 
CAT in the Middle East to identify people at risk for COPD 
in the general population.14
COPD screening with questionnaires and pulmonary 
function testing have been found to be useful methods for the 
early detection and treatment of COPD.15 Another question-
naire that has been successfully utilized to screen for COPD 
patients in Japan is the 11-Q, which consists of eleven items, 
including smoking status, age, cough, phlegm, and shortness 
of breath.16 Other diagnostic COPD-screening tools include 
the Lung Function Questionnaire17 and the COPD Popula-
tion Screener.18 These are specific instruments for screening 
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Table 2 Characteristics of the population in each CAt category (studies 1 and 2 combined)
Total 
(n=3,062)
CAT 0–9 
(n=2,141)
CAT 10–19 
(n=785)
CAT 20–29 
(n=130)
CAT $30 
(n=6)
P-value
Age
 Mean (sD) 61.5 (11.6) 62.0 (11.5) 60.1 (11.8) 62.4 (11.6) 67.7 (6.4) 0.001*
sex
 Male, % 88.8% 89.0% 89.0% 83.8% 83.3% 0.322**
smoking history
 Current (%) 44.9% 40.3% 40.3% 57.7% 33.3% 0.001**
 ex (%) 55.1% 59.7% 59.7% 42.3% 66.7%
smoking, pack-years
 Mean (sD) 37.3 (23.5) 36.5 (23.1) 36.5 (23.1) 43.5 (29.5) 33.0 (17.7) 0.003*
BMI
 Mean (sD) 24.2 (3.4) 24.1 (3.3) 24.1 (3.3) 24.4 (3.8) 24.5 (3.9) 0.322*
Diagnosed with COPD
 Diagnosed 1.6% 1.2% 2.0% 5.4% 0.0% 0.001**
Chronic sputum
 Yes 19.7% 13.7% 31.6% 46.2% 33.3% 0.001**
Fev1
 Mean (sD) 2.52 (0.76) 2.54 (0.74) 2.53 (0.79) 2.19 (0.87) 2.17 (0.77) 0.001*
Fev6
 Mean (sD) 3.21 (0.87) 3.22 (0.86) 3.32 (0.87) 2.88 (0.97) 2.71 (0.97) 0.001*
Airflow limitation
 Fev1/Fev6 ,0.73 21.8% 19.6% 26.0% 33.8% 16.7% 0.001**
 Fev1/Fev6 $0.73 78.2% 81.4% 74.0% 66.2% 83.3%
CAt score
 Mean (sD) 7.4 (5.9) 4.2 (2.7) 13.1 (2.5) 23.1 (2.7) 35.3 (4.1)
Notes: *Analysis of variance; **χ2. P-value calculated for comparison between the CAt categories.
Abbreviations: sD, standard deviation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 1 second; Fev6, forced 
expiatory volume in 6 seconds; CAt, COPD Assessment test.
for COPD, unlike the CAT, which is an assessment and 
monitoring tool. However, the potential advantage of the 
CAT as a case-finding instrument is that doctors in routine 
care would only need one instrument for multiple purposes, 
thereby potentially reducing the barriers to finding patients 
with COPD.
The purpose of this analysis was to identify a CAT score 
that would reasonably suggest spirometry is required to con-
firm or otherwise a diagnosis of COPD. We combined data 
from two studies to increase statistical power and increase 
heterogeneity in the study populations. The Hi-Checker 
spirometer was used, since it is inexpensive and convenient 
for checking FEV
1
 and obstructive lung disorders.8 It has 
been shown to correlate with conventional spirometry,8,19 
although one study showed that it did not produce identical 
results to a conventional spirometer.20 In both of these stud-
ies, a large number of previously undiagnosed patients were 
identified as having airflow limitation, defined as an FEV
1
/
FEV
6
 ratio ,0.73.13 A total of 21.8% of subjects were identi-
fied, of whom only 1.6% had a previous diagnosis of COPD. 
In study 1, in patients presenting to the clinic with winter 
bronchitis and recurrent chest infections, airflow limitation 
was seen in 19.4% of the population.21 In study 2, 27% of 
patients attending a cardiovascular clinic had airflow limi-
tation, of whom 4.8% had a previous diagnosis of COPD.8 
This confirms the high level of undiagnosed COPD in Japan 
reported in previous studies,4–6 such as the Nippon COPD 
Epidemiology study, which showed a prevalence of 10.9% 
in subjects aged $40 years.4 We acknowledge that the lack 
of postbronchodilator lung-function data is a limitation in 
these studies.
In the patients with airflow limitation, the CAT score 
was 8.6 and 8.3 in studies 1 and 2, respectively, compared 
to 7.4 and 6.4, respectively, in patients without airflow 
limitation. These scores are similar to those reported in 
healthy Japanese workers (some of whom were also found 
to have had airflow limitation).22 This score is lower than 
that seen in patients previously diagnosed with COPD in 
Europe,11 and suggests that patients in our studies had not 
been diagnosed previously because they had a low level 
of symptoms when stable. This conclusion is compatible 
with a previous observation that patients who had COPD 
diagnosed through a spirometry screening program had 
much lower St George’s Respiratory Questionnaire scores 
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Figure 2 CAt score by age (years).
Abbreviations: COPD, chronic obstructive pulmonary disease; CAt, COPD Assessment test.
Table 3 Summary of lung-function data for patients with and without airflow limitation from both studies
Total 
(n=3,062)
Study 1 
(n=2,067)
Study 2 
(n=995)
FEV1/FEV6 ,0.73 FEV1/FEV6 ,0.73 FEV1/FEV6 $0.73 FEV1/FEV6 $0.73
Study 1 
(n=400)
Study 2 
(n=269)
Study 1 
(n=1,667)
Study 2 
(n=726)
Fev1
 Mean 2.523 2.634 2.292 2.007 1.776 2.784 2.483
 sD 0.7623 0.7642 0.7046 0.7095 0.6451 0.6976 0.6259
 95% CI 2.49–2.55 2.60–2.67 2.25–2.33 1.94–2.08 1.60–1.85 2.75–2.82 2.44–2.53
 Median 2.51 2.64 2.29 2.03 1.75 2.78 2.45
 Min 0.41 0.41 0.49 0.41 0.49 0.63 0.58
 Max 4.88 4.88 4.84 3.91 3.98 4.88 4.84
Fev6
 Mean 3.21 3.33 2.97 3.08 2.79 3.39 3.03
 sD 0.87 0.88 0.79 0.94 0.81 0.85 0.77
 95% CI 3.18–3.24 3.29–3.37 2.92–3.02 2.98–3.17 2.69–2.89 3.35–3.44 2.98–3.00
 Median 3.19 3.31 2.95 3.11 2.82 3.37 3.00
 Min 0.60 0.60 0.74 0.60 0.92 0.83 0.74
 Max 6.49 6.49 6.31 5.52 5.47 6.49 6.31
Abbreviations: Fev1, forced expiratory volume in 1 second; Fev6, forced expiatory volume in 6 seconds; SD, standard deviation; CI, confidence interval; Min, minimum; 
Max, maximum.
than those with a previous physician’s diagnosis of COPD.22 
Health status and level of physical activity are not only 
markers of health but also predictors of survival in patients 
with COPD23–25; even COPD patients with GOLD ( Global 
initiative for chronic Obstructive Lung Disease) grade 1 
disease have an increased risk of mortality, so it is important 
to find and treat these patients.26 It has also been shown that 
subjects with higher CAT scores were more likely to report 
recent exacerbations,10 so the CAT may also have a potential 
role as a case-finding tool to identify people at greater risk 
of exacerbation and hospitalization.
The choice of cut points always involves value judg-
ments, in terms of the balance between sensitivity and effi-
cacy (due to false-positive rates). Such judgments will also 
be influenced by the application to which an instrument is 
being used, eg, whether it is to be used to make a definitive 
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Table 4 Calculated false-negative and false-positive values and 
the sensitivity and specificity of CAT scores 7–10
 False  
negative
False  
positive
Sensitivity Specificity
CAt 7 66.2% 75.8% 0.517 0.548
CAt 8 52.1% 74.8% 0.474 0.607
CAt 9 39.8% 73.9% 0.419 0.669
CAt 10 31.4% 73.0% 0.372 0.719
Abbreviations: COPD, chronic obstructive pulmonary disease; CAt, COPD 
Assessment test.
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Figure 3 Percentage of patients with airflow limitation split by CAT score.
Abbreviations: COPD, chronic obstructive pulmonary disease; CAt, COPD 
Assessment test.
diagnosis or used as a case-finding tool to identify patients for 
whom another definitive test would be needed. This analysis 
explored the possible application of the CAT as a quick and 
economical case-finding tool, not as a diagnostic instru-
ment, so a high level of efficiency would not be expected. 
The false-positive rate remained constant across a range of 
potential cut points, and a CAT score of 10 seems to provide 
a reasonable compromise, with the added convenience that it 
is also the threshold recommended by GOLD for introducing 
maintenance symptomatic treatment, so practitioners would 
only need to remember one CAT score for two purposes. 
There may be a concern about the use of the CAT to iden-
tify cases of COPD in cardiac disease clinics, because of 
shared symptoms that might result in an unacceptably high 
false-positive rate; however, that is unlikely to be the case. 
Two studies with the CAT have shown that cardiovascular 
comorbidity in COPD patients has little or no effect on the 
CAT score.27,28
In conclusion, early detection of COPD is still an unre-
solved issue in Japan, as elsewhere in the world. In a study 
by Omori et al,7 it was shown that early stages of COPD can 
be detected on medical checkup in Japan. Use of the CAT 
as a case-finding tool may assist this process by identifying 
people who need spirometry for possible diagnosis of COPD, 
especially smokers with cardiovascular disease and patients 
with frequent episodes of acute bronchitis.
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